Protara Therapeutics Launches $100M At-The-Market Offering

summarizeSummary

Protara Therapeutics has launched its previously announced At-The-Market (ATM) offering, allowing it to sell up to $100 million of common stock to fund its clinical development programs and general corporate purposes.

check_boxKey Events · Financing and Capital Events · TARA

• At-The-Market Offering Launched

  Protara Therapeutics has launched an At-The-Market (ATM) offering, allowing it to sell up to $100,000,000 of common stock from time to time through TD Cowen. This finalizes terms of the offering initiated with the S-3 filing on May 13, 2026.

• Significant Potential Dilution

  The offering represents a potential dilution of approximately 37% of the company's current market capitalization and over 34% of outstanding shares, based on an assumed offering price of $5.21 per share.

• Use of Proceeds

  Net proceeds from the offering are intended to fund the clinical development of TARA-002 and IV Choline Chloride, as well as for working capital and other general corporate purposes.

• Capital for Clinical Programs

  As a clinical-stage biopharmaceutical company with no approved products or product sales revenue, this capital raise is crucial for funding ongoing and future clinical trials for its pipeline candidates.

auto_awesomeAnalysis · TARA · Life Sciences

This 424B5 filing operationalizes the $100 million At-The-Market (ATM) offering previously registered via an S-3 on May 13, 2026. The company may sell up to $100 million in common stock, which represents a substantial potential dilution of approximately 37% of its current market capitalization and over 34% of outstanding shares. While dilutive, this capital raise is critical for Protara, a clinical-stage biopharmaceutical company, to fund its ongoing and future clinical trials for TARA-002 (in NMIBC and LMs) and IV Choline Chloride, extending its cash runway.